A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer

被引:59
作者
Elsaesser-Beile, Ursula
Wolf, Philipp
Gierschner, Dorothee
Buehler, Patrick
Schultze-Seemann, Wolfgang
Wetterauer, Ulrich
机构
[1] Univ Freiburg, Expt Res Grp, Dept Urol, D-79106 Freiburg, Germany
[2] Univ Freiburg, Fac Biol, D-79106 Freiburg, Germany
关键词
PSMA; mAb; scFv; prostate cancer; tumor targeting;
D O I
10.1002/pros.20367
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND. Prostate-specific membrane antigen (PSMA) is an excellent candidate for targeting prostate cancer by virtue of its restricted expression on prostatic epithelial cells and its upregulation on prostatic carcinoma cells. PSMA is expressed on the cell surface displaying a specific three-dimensional structure. Therefore, only antibodies with a high cell binding activity will have an important impact on antibody-based imaging and therapy. METHODS. Monoclonal antibodies (mAbs) and single chain antibody fragments (scFvs) were prepared from spleen cells of mice that had been immunized either with purified PSMA or a cell lysate of prostate cancer LNCaP cells containing native PSMA. mAbs and scFvs were screened for reactivity with purified PSMA and binding to PSMA-expressing LNCaP cells. RESULTS. From mice immunized with purified PSMA, we obtained three mAbs (K7, K12, D20) and four scFvs (G0, G1, G2, G4), which were highly reactive with the isolated antigen, but showed weak or no reaction with viable LNCaP cells. From mice immunized with unpurified LNCaP lysate, we obtained three mAbs (3/E7, 3/F11, 3/A12), and one scFv (A5), which were reactive with purified PSMA, also showing a strong and specific binding to viable LNCaP cells and PSMA-transfected cells. CONCLUSIONS. Our results suggest that only the mAbs and scFvs, that were elicited with unpurified LNCaP lysate and not with purified PSMA will be useful agents for diagnostic imaging and therapeutic applications of prostate cancer.
引用
收藏
页码:1359 / 1370
页数:12
相关论文
共 31 条
[1]   Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen [J].
Bander, NH ;
Trabulsi, EJ ;
Kostakoglu, L ;
Yao, D ;
Vallabhajosula, S ;
Smith-Jones, P ;
Joyce, MA ;
Milowsky, M ;
Nanus, DM ;
Goldsmith, SJ .
JOURNAL OF UROLOGY, 2003, 170 (05) :1717-1721
[2]   Identification of the N-glycosylation sites on glutamate carboxypeptidase II necessary for proteolytic activity [J].
Barinka, C ;
Sacha, P ;
Sklenar, J ;
Man, P ;
Bezouska, K ;
Slusher, BS ;
Konvalinka, J .
PROTEIN SCIENCE, 2004, 13 (06) :1627-1635
[3]  
Bostwick DG, 1998, CANCER-AM CANCER SOC, V82, P2256, DOI 10.1002/(SICI)1097-0142(19980601)82:11<2256::AID-CNCR22>3.0.CO
[4]  
2-S
[5]  
Chang SS, 1999, CANCER RES, V59, P3192
[6]   Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase [J].
Davis, MI ;
Bennett, MJ ;
Thomas, LM ;
Bjorkman, PJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (17) :5981-5986
[7]   Anti-tumor effects of toxins targeted to the prostate specific membrane antigen [J].
Fracasso, G ;
Bellisola, G ;
Cingarlini, S ;
Castelletti, D ;
Prayer-Galetti, T ;
Pagano, F ;
Tridente, G ;
Colombatti, M .
PROSTATE, 2002, 53 (01) :9-23
[8]  
FUCHS P, 1992, CELL BIOPHYS, V21, P81, DOI 10.1007/BF02789480
[9]   RAT-X-RAT HYBRID MYELOMAS AND A MONOCLONAL ANTI-FD PORTION OF MOUSE IGG [J].
GALFRE, G ;
MILSTEIN, C ;
WRIGHT, B .
NATURE, 1979, 277 (5692) :131-133
[10]   Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer [J].
Ghosh, A ;
Heston, WDW .
JOURNAL OF CELLULAR BIOCHEMISTRY, 2004, 91 (03) :528-539